Page last updated: 2024-08-25

almagate and Retinal Diseases

almagate has been researched along with Retinal Diseases in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (45.00)	29.6817
2010's	10 (50.00)	24.3611
2020's	1 (5.00)	2.80

Authors

Authors	Studies
Marko, CK; Miller, JW	1
AbouChehade, JE; Bakri, SJ; Dalvin, LA; Damento, GM; Garcia, MD; Hodge, DO; Iezzi, R; Meissner, I; Shah, SM; Starr, MR	1
Nuzzi, R; Tridico, F	1
Agrawal, S; Christoforidis, JB; Joshi, M	1
Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Fortun, JA; Gregori, NZ; Kovach, JL; Moshfeghi, AA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE; Vaziri, K	1
Chen, Q; Chen, W; Gao, Z; Huang, D; Huang, L; Ju, R; Kumar, A; Lee, C; Li, X; Liu, L; Mi, J; Ren, X; Tang, Z; Tian, G; Wang, B; Wang, S; Xing, L; Ye, Z; Zhang, S; Zhao, C; Zheng, L	1
Brasil, OF; Burnier, MN; Squeri, G; Turquetti, R; Vianna, RN	1
Covert, DJ; Hur, EY; Kim, JE; Mantravadi, AV	1
Calvo-González, C; Donate-López, J; García-Feijoó, J; García-Sánchez, J; Leila, M; Molina Guilabert, I; Reche-Frutos, J	1
Giuliari, GP; Hinkle, DM; Sadaka, A; Simpson, ER	1
Brown, DM; Chen, E; Cox, J; Lin, MY	1
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B	1
Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF	1
Chen, TC; Englander, M; Kim, IK; Miller, JW; Paschalis, EI	1
Jain, A; Moshfeghi, DM; Sun, Y	1
Joussen, AM	1
Bakri, SJ; Diehl, N; Hillemeier, J; Hodge, DO; McCannel, CA; Pulido, JS	1
Kompella, UB	1
Capone, A; Drenser, KA; Lai, MM; Quiram, PA; Trese, MT	1
Harding, SP; Heimann, H; Kumar, N; Lenfestey, PM; Mahmood, S; Murjaneh, S	1

Reviews

3 review(s) available for almagate and Retinal Diseases

Article	Year
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators of inflammation, 2013, Volume: 2013 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Humans; Infant, Newborn; Inflammation; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Risk; Vascular Endothelial Growth Factor A; Vitreous Body	2013
Current treatments for radiation retinopathy. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Brachytherapy; Eye Neoplasms; Head and Neck Neoplasms; Humans; Laser Coagulation; Light Coagulation; Low-Level Light Therapy; Pentoxifylline; Photochemotherapy; Radiation Injuries; Ranibizumab; Retina; Retinal Diseases; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A	2011
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]. Deutsche medizinische Wochenschrift (1946), 2007, Jun-08, Volume: 132, Issue:23 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases	2007

Other Studies

17 other study(ies) available for almagate and Retinal Diseases

Article	Year
Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2021, Volume: 49, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Humans; Photochemotherapy; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Research; Research Support as Topic; Retinal Diseases; Translational Research, Biomedical; Vascular Endothelial Growth Factor A	2021
Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmic surgery, lasers & imaging retina, 2019, 05-01, Volume: 50, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Dihydropyridines; Female; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Retrospective Studies; Stroke; Vascular Endothelial Growth Factor A	2019
Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Seminars in ophthalmology, 2015, Volume: 30, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Follow-Up Studies; Humans; Incidence; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Odds Ratio; Ranibizumab; Retinal Detachment; Retinal Diseases; Retinal Hemorrhage; Retrospective Studies; Uveitis; Vascular Endothelial Growth Factor A	2015
Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment. Ophthalmic surgery, lasers & imaging retina, 2015, Volume: 46, Issue:6 Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Florida; Humans; Incidence; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity	2015
VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis. Scientific reports, 2016, 05-18, Volume: 6 Topics: Animals; Apoptosis; Aptamers, Nucleotide; Diabetes Mellitus, Experimental; Mice, Inbred C57BL; Rats; Retinal Diseases; Retinal Ganglion Cells; Treatment Outcome; Vascular Endothelial Growth Factor B	2016
Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2008, Volume: 43, Issue:4 Topics: Aptamers, Nucleotide; Capillary Permeability; Female; Fluorescein; Fluorescein Angiography; Fovea Centralis; Humans; Injections; Middle Aged; Retinal Diseases; Retinal Vessels; Telangiectasis; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body	2008
Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. American journal of ophthalmology, 2008, Volume: 146, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug Monitoring; Female; Humans; Injections; Intraocular Pressure; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Time Factors; Tonometry, Ocular; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Vitreous Body	2008
Intravitreal pegabtanib sodium in choroidal neovascularization secondary to angioid streaks. Acta ophthalmologica, 2009, Volume: 87, Issue:5 Topics: Adult; Angiogenesis Inhibitors; Angioid Streaks; Aptamers, Nucleotide; Choroidal Neovascularization; Edema; Fluorescein Angiography; Humans; Injections; Male; Retinal Detachment; Retinal Diseases; Tomography, Optical Coherence; Vitreous Body	2009
Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Glucocorticoids; Humans; Incidence; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Risk Factors; Streptococcal Infections; Triamcinolone Acetonide; Viridans Streptococci; Visual Acuity; Vitreous Body	2011
[Complications of intravitreal injections--own experience]. Klinika oczna, 2011, Volume: 113, Issue:4-6 Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity	2011
[Intravitreal injections: AFSSAPS guide to good practice]. Journal francais d'ophtalmologie, 2012, Volume: 35, Issue:1 Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical	2012
Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. The British journal of ophthalmology, 2013, Volume: 97, Issue:4 Topics: Academic Medical Centers; Acute Disease; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Incidence; Intravitreal Injections; Male; Massachusetts; Postoperative Complications; Ranibizumab; Retinal Diseases; Retrospective Studies; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity	2013
Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2007, Volume: 245, Issue:9 Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Child, Preschool; Humans; Injections; Male; Retinal Diseases; Retinal Vessels; Telangiectasis; Vascular Endothelial Growth Factor A; Vitreous Body	2007
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (London, England), 2009, Volume: 23, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Injections, Intralesional; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Paracentesis; Remission, Spontaneous; Retinal Diseases; Triamcinolone	2009
Drug delivery to the back of the eye. Archivos de la Sociedad Espanola de Oftalmologia, 2007, Volume: 82, Issue:11 Topics: Antiviral Agents; Aptamers, Nucleotide; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Delivery Systems; Eye Diseases; Glaucoma; Humans; Injections; Macular Degeneration; Nanoparticles; Oligonucleotides, Antisense; Ophthalmic Solutions; Retinal Diseases; Thionucleotides; Vascular Endothelial Growth Factor A	2007
Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:3 Suppl Topics: Adolescent; Aptamers, Nucleotide; Child, Preschool; Female; Humans; Injections; Male; Retinal Diseases; Retrospective Studies; Treatment Outcome; Visual Acuity; Young Adult	2008
Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review. Eye (London, England), 2009, Volume: 23, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiomatosis; Aptamers, Nucleotide; Drug Evaluation; Female; Follow-Up Studies; Humans; Injections, Intraocular; Macular Degeneration; Male; Middle Aged; Retinal Diseases; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity	2009